If datopotamab deruxtecan (Dato-DXd) is approved for first-line metastatic TNBC, it could significantly influence clinical practice by providing an effective option for patients, particularly those ineligible for immunotherapy or with PD-L1–negative disease.
Pharmacists play a critical role in educating patients about potential side effects, monitoring for early signs of toxicity, and coordinating supportive care measures, including growth factor support for hematologic events.
New findings on nodal radiation for breast cancer patients highlight the importance of lymph node involvement and tumor size in treatment decisions.
The FLEX study enhances breast cancer treatment by integrating genomic data, guiding therapy choices, and improving patient outcomes.
Studying antibody–drug conjugates (ADCs) in patients ineligible for immunotherapy addresses a critical unmet need in PD-L1–negative metastatic TNBC, where targeted treatment options are limited.
If sacituzumab govitecan (SG) is approved for first-line metastatic TNBC, it could meaningfully shift clinical practice by providing an effective option for patients ineligible for immunotherapy or with PD-L1–negative disease.
Explore the complexities of hemophilia, its severity spectrum, and the emotional impact on patients and families in this insightful discussion.
Explore the latest FDA-approved therapies for non-small cell lung cancer, focusing on EGFR mutations and treatment strategies in oncology.
In the final segment, the panelists bring together the major insights from across the series, highlighting the most clinically meaningful data from monarchE, NATALEE, and VIKTORIA-1 and what these findings mean for the evolving role of CDK4/6 inhibitors in both early-stage and metastatic HR+ breast cancer.
Health care professionals discuss the risks of tardive dyskinesia in patients on dopamine receptor antagonists and emphasize the importance of education and monitoring.
Explore key updates in hemophilia management, focusing on patient support, bleeding management, and the pharmacist's vital role in treatment.
Experts discuss practical strategies for early recognition and coordinated care of tardive dyskinesia to enhance patient outcomes and quality of life.
Navigating FDA-Approved EGFR-Targeted Therapies in NSCLC
In this segment, the experts turn their attention to metastatic HR+/HER2– breast cancer, examining the first results from the VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib.
Prateek Bhatia discusses optimizing staffing and workflows in infusion centers to enhance patient care and reduce delays in treatment.
IV compounding robotics and next-generation dispensing technology enhance pharmacy workflows, boost staff engagement, and improve patient care outcomes.
Pharmacists explore new breast cancer therapies and management strategies, enhancing patient care and treatment outcomes at SABCS.
Heidi De Souza, MPH, reveals low RSV vaccine uptake among older adults, highlighting disparities and barriers that hinder access and awareness post-FDA approval.
Oncology pharmacists discuss myelofibrosis management, focusing on anemia, JAK inhibitors, and improving patient outcomes through tailored care.
Explore expert insights on managing myelofibrosis, focusing on anemia, JAK inhibitors, and enhancing patient care for better outcomes.
GLP-1 medications show promise in reducing chemotherapy side effects and improving heart health in breast cancer patients, warranting further research.
Clinicians learn to optimize type 2 diabetes treatment using automated insulin delivery data, enhancing patient safety and education for effective management.
Experts discuss innovations in medication-use processes at the ASHP Midyear Meeting, highlighting trends in acute and ambulatory care for pharmacy leaders.
Patients learn the importance of understanding treatment-related skin issues, recognizing symptoms, and adopting gentle skincare practices for better management.
A pharmacist-led deep vein thrombosis (DVT) clinic revolutionizes outpatient care, reducing emergency visits and costs while enhancing medication adherence through collaborative practices.
Because ASCENT-03 allowed crossover and more than half of patients received subsequent therapy, overall survival is unlikely to show a statistically significant difference, even if a clinical benefit exists.
The ASCENT-03 trial, presented at ESMO and published in NEJM, evaluated sacituzumab govitecan (SG) versus physician’s-choice chemotherapy—including paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin—in patients with metastatic TNBC who were either PD-L1–negative or not candidates for immunotherapy.
